Autoimmune Disease clinical trials at UCSF
7 in progress, 6 open to eligible people
Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
open to eligible people ages 18 years and up
Interstitial lung disease (ILD) is a lung condition resulting in inflammation and stiffening of the lung, often associated with connective tissue diseases (CTDs). ILD causes reduction in lung volume, shortness of breath, cough and fatigue therefore has high impact on quality of life and is also the leading cause of death in participants with these conditions. The study will assess whether treatment of CTD-ILD participants with belimumab in addition to standard therapy will result in the stabilization and/or improvement of lung function and improve symptoms associated with ILD with an acceptable safety profile.
San Francisco 5391959, California 5332921 and other locations
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
open to eligible people ages 18-70
RESET-MG: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Participants with Generalized Myasthenia Gravis
San Francisco 5391959, California 5332921 and other locations
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
open to eligible people ages 6-75
RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
San Francisco 5391959, California 5332921 and other locations
Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
open to eligible people ages 18-70
This study will test the safety and effects of SBT777101 when given as a single dose to subjects with rheumatoid arthritis. It is the first study of this treatment being done in humans. Increasing dose levels will be given after the safety at lower dose levels is shown.
San Francisco 5391959, California 5332921 and other locations
Access the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
open to eligible people ages 18-75
This is a 26-week study to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.
San Francisco 5391959, California 5332921 and other locations
Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
open to all eligible people
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Oakland 5378538, California 5332921 and other locations
Alopecia Areata Registry
Sorry, in progress, not accepting new patients
Alopecia areata is the loss of hair in patches that can proceed to loss of all hair (alopecia totalis or universalis). The purpose of the registry is to collect patient information and blood samples from people with alopecia areata.
San Francisco 5391959, California 5332921 and other locations
Our lead scientists for Autoimmune Disease research studies include Dr. Min Kang, MD Susan Kim, MD, MMSc Sandhya Kharbanda.
Last updated: